Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran



Seyedifar M1 ; Dorkoosh FA2 ; Hamidieh AA3 ; Naderi M4 ; Karami H5 ; Karimi M6 ; Fadaiyrayeny M3 ; Musavi M4 ; Safaei S7 ; Ahmadianattari MM8 ; Hadjibabaie M9, 10 ; Cheraghali AM11 ; Sari AA12
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pediatrics Hematology-Oncology, Ali-Ebne Abitaleb Hospital Research Center for Children and Adolescent Health [RCCAH], Zahedan University of Medical Sciences, Zahedan, Iran
  5. 5. Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran
  6. 6. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  7. 7. MSc Student of Nursing, Islamic Azad University, Isfahan (Khorasgan) Branch, Isfahan, Iran
  8. 8. Department of Traditional Medicine, Medicinal Plants Research Center of Barij, Kashan, Iran
  9. 9. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
  10. 10. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  11. 11. Faculty of Pharmacy, University of Baqiyatallah Medical Sciences, Tehran, Iran
  12. 12. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal of Hematology-Oncology and Stem Cell Research Published:2016

Abstract

Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations. Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender. Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 i¿½ .01 for oral iron chelators versus 0.81 i¿½ .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males. Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in. i¿½ 2016, Tehran University of Medical Sciences (TUMS). All rights reserved.